BioMarin surpasses $1 billion revenue for the first time in Q3 2026
FROM THE WIRE · FINANCE.YAHOO.COM
This article first appeared on GuruFocus. Total Revenue: Surpassed $1 billion for the first time in company history; grew 32% year-over-year in Q3 2026. Metabolic Conditions Revenue: $744 million, up 44% year-over-year, driven largely by first full quarter of GALAFOLD and…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishStrong revenue growth led by metabolic drugs is a positive signal for the biotech stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Total revenue grew 32% year-over-year in Q3 2026, surpassing $1 billion for the first time.
- 02Metabolic conditions revenue reached $744 million, up 44% year-over-year.
- 03VOXZOGO revenue was $245 million, up 12% year-over-year.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
BioMarin Pharmaceutical Inc.55.66 USDMarket closedtoday -3.10%Positive BIOMARIN PHARM50.00 EURMarket closedtoday -4.34%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets